Adial Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Adial Pharmaceuticals, Inc. (ADIL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.26 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $1.26M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2018-12-31 | $1.26M 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |